CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional Phase 1 trials

Abstract Cibisatamab is a bispecific antibody-based construct targeting carcinoembryonic antigen (CEA) on tumour cells and CD3 epsilon chain as a T-cell engager. Here we evaluated cibisatamab for advanced CEA-positive solid tumours in two open-label Phase 1 dose-escalation and -expansion studies: as...

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	Neil H. Segal, Ignacio Melero, Victor Moreno, Neeltje Steeghs, Aurelien Marabelle, Kristoffer Rohrberg, Maria E. Rodriguez-Ruiz, Joseph P. Eder, Cathy Eng, Gulam A. Manji, Daniel Waterkamp, Barbara Leutgeb, Said Bouseida, Nick Flinn, Meghna Das Thakur, Markus C. Elze, Hartmut Koeppen, Candice Jamois, Meret Martin-Facklam, Christopher H. Lieu, Emiliano Calvo, Luis Paz-Ares, Josep Tabernero, Guillem Argilés
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	Nature Portfolio 2024-05-01
Schriftenreihe:	Nature Communications
Online-Zugang:	https://doi.org/10.1038/s41467-024-48479-8
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!